Cemiplimab-Associated Sinusoidal Obstruction Syndrome.
Publication/Presentation Date
4-1-2023
Abstract
A 58-year-old woman developed new-onset recurrent ascites after the recent initiation of cemiplimab for the treatment of advanced basal cell carcinoma. A comprehensive serological workup for viral, metabolic, and autoimmune causes was unrevealing. Transjugular liver biopsy demonstrated parenchymal changes consistent with a diagnosis of sinusoidal obstruction syndrome. While this is a condition commonly observed in patients after hematopoietic stem cell transplantation or use of chemotherapeutic agents, it should also be considered in patients who develop new-onset liver dysfunction after the initiation of checkpoint inhibitors.
Volume
10
Issue
4
First Page
01038
Last Page
01038
ISSN
2326-3253
Published In/Presented At
Sarsour, N. Y., Minervini, M., & Malik, S. M. (2023). Cemiplimab-Associated Sinusoidal Obstruction Syndrome. ACG case reports journal, 10(4), e01038. https://doi.org/10.14309/crj.0000000000001038
Disciplines
Medicine and Health Sciences
PubMedID
37091208
Department(s)
Department of Medicine
Document Type
Article
